Individualization of therapy based on clinical and molecular parameters

Current Colorectal Cancer Reports

Volumn 4, Issue 4, 2008, Pages 193-200

  Lurje, Georg ^b   Pohl, Alexandra ^b   Manegold, Phillip C ^b   Lenz, Heinz Josef ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

EID: 67349231607     PISSN: 15563790     EISSN: 15563804     Source Type: Journal    
DOI: 10.1007/s11888-008-0031-0     Document Type: Article

References (52)

1. de Gramont A, Figer A, Seymour M, et al.: Leucovorin and fuorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2000, 18: 2938-2947.
2. Douillard JY, Cunningham D, Roth AD, et al.: Irinotecan combined with fuorouracil compared with fuorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet 2000, 355: 1041-1047 [Published erratum appears in Lancet 2000, 355: 1372.].
3. Grothey A, Sargent D, Goldberg RM, Schmoll HJ: Survival of patients with advanced colorectal cancer improves with the availability of f uorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment. J Clin Oncol 2004, 22: 1209-1214.
4. Compton CC, Greene FL: The staging of colorectal cancer: 2004 and beyond. CA Cancer J Clin 2004, 54: 295-308.
5. Wiggers T, Arends JW, Schutte B, et al.: A multivariate analysis of pathologic prognostic indicators in large bowel cancer. Cancer 1988, 61: 386-395.
6. Shepherd NA, Baxter KJ, Love SB: The prognostic importance of peritoneal involvement in colonic cancer: a prospective evaluation. Gastroenterology 1997, 112: 1096-1102.
7. Benson AB 3rd, Schrag D, Somerf eld MR, et al.: American Society of Clinical Oncology recommendations on adjuvant chemotherapy for stage II colon cancer. J Clin Oncol 2004, 22: 3408-3419.
8. Le Voyer TE, Sigurdson ER, Hanlon AL, et al.: Colon cancer survival is associated with increasing number of lymph nodes analyzed: a secondary survey of intergroup trial INT-0089. J Clin Oncol 2003, 21: 2912-2919.
9. Chang GJ, Rodriguez-Bigas MA, Skibber JM, Moyer VA: Lymph node evaluation and survival after curative resection of colon cancer: systematic review. J Natl Cancer Inst 2007, 99: 433-441.
10. Cooper HS, Deppisch LM, Gourley WK, et al.: Endoscopi-cally removed malignant colorectal polyps: clinicopathologic correlations. Gastroenterology 1995, 108: 1657-1665.
11. Greene FL, Page DL, Fleming HM: Cancer Staging Manual. In AJCC Cancer Staging Manual, edn 6. New York: Springer-Verlag; 2002.
12. Newland RC, Dent OF, Lyttle MN, et al.: Pathologic determinants of survival associated with colorectal cancer with lymph node metastases. A multivariate analysis of 579 patients. Cancer 1994, 73: 2076-2082.
13. Goldstein NS, Hart J: Histologic features associated with lymph node metastasis in stage T1 and superf cial T2 rectal adenocarcinomas in abdominoperineal resection specimens. Identifying a subset of patients for whom treatment with adjuvant therapy or completion abdominoperineal resection should be considered after local excision. Am J Clin Pathol 1999, 111: 51-58.
14. Louhimo J, Carpelan-Holmstrom M, Alfthan H, et al.: Serum HCG beta, CA 72-4 and CEA are independent prognostic factors in colorectal cancer. Int J Cancer 2002, 101: 545-548.
15. Wanebo HJ, Rao B, Pinsky CM, et al.: Preoperative carcinoembryonic antigen level as a prognostic indicator in colorectal cancer. N Engl J Med 1978, 299: 448-451.
16. Hayes DF, Bast RC, Desch CE, et al.: Tumor marker utility grading system: a framework to evaluate clinical utility of tumor markers. J Natl Cancer Inst 1996, 88: 1456-1466.
17. Thibodeau SN, Bren G, Schaid D: Microsatellite instability in cancer of the proximal colon. Science 1993, 260: 816-819.
18. Watanabe T, Wu TT, Catalano PJ, et al.: Molecular predictors of survival after adjuvant chemotherapy for colon cancer. N Engl J Med 2001, 344: 1196-1206.
19. Ionov Y, Peinado MA, Malkhosyan S, et al.: Ubiquitous somatic mutations in simple repeated sequences reveal a new mechanism for colonic carcinogenesis. Nature 1993, 363: 558-561.
20. Kinzler KW, Vogelstein B: Lessons from hereditary colorec-tal cancer. Cell 1996, 87: 159-170.
21. Carethers JM, Chauhan DP, Fink D, et al.: Mismatch repair prof ciency and in vitro response to 5-f uorouracil. Gastroenterology 1999, 117: 123-131.
22. Kim GP, Colangelo LH, Wieand HS, et al.: Prognostic and predictive roles of high-degree microsatellite instability in colon cancer: a National Cancer Institute-National Surgical Adjuvant Breast and Bowel Project Collaborative Study. J Clin Oncol 2007, 25: 767-772.
23. Popat S, Hubner R, Houlston RS: Systematic review of microsatellite instability and colorectal cancer prognosis. J Clin Oncol 2005, 23: 609-618.
24. Vogelstein B, Fearon ER, Hamilton SR, et al.: Genetic alterations during colorectal-tumor development. N Engl J Med 1988, 319: 525-532.
25. Fearon ER, Cho KR, Nigro JM, et al.: Identif cation of a chromosome 18q gene that is altered in colorectal cancers. Science 1990, 247: 49-56.
26. Keino-Masu K, Masu M, Hinck L, et al.: Deleted in Colorectal Cancer (DCC) encodes a netrin receptor. Cell 1996, 87: 175-185.
27. Popat S, Houlston RS: A systematic review and meta-analy-sis of the relationship between chromosome 18q genotype, DCC status and colorectal cancer prognosis. Eur J Cancer 2005, 41: 2060-2070.
28. Oxaliplatin, Leucovorin, and Fluorouracil With or Without Bevacizumab in Treating Patients Who Have Undergone Surgery for Stage II Colon Cancer. Available at: http://clini-caltrials.gov/ct/show/NCT00217737. Accessed July 19, 2007.
29. Salonga D, Danenberg KD, Johnson M, et al.: Colorectal tumors responding to 5-f uorouracil have low gene expression levels of dihydropyrimidine dehydrogenase, thymidylate synthase, and thymidine phosphorylase. Clin Cancer Res 2000, 6: 1322-1327.
30. Popat S, Matakidou A, Houlston RS: Thymidylate synthase expression and prognosis in colorectal cancer: a systematic review and meta-analysis. J Clin Oncol 2004, 22: 529-536.
31. Lurje G, Zhang W, Yang D, et al.: Thymidylate synthase haplotype is associated with tumor recurrence in stage II and stage III colon cancer. Pharmacogenet Genomics 2008, 18: 161-168.
32. Pullarkat ST, Stoehlmacher J, Ghaderi V, et al.: Thymi-dylate synthase gene polymorphism determines response and toxicity of 5-FU chemotherapy. Pharmacogenomics J 2001, 1: 65-70.
33. Iacopetta B, Grieu F, Joseph D, Elsaleh H: A polymorphism in the enhancer region of the thymidylate synthase promoter inf uences the survival of colorectal cancer patients treated with 5-f uorouracil. Br J Cancer 2001, 85: 827-830.
34. McLeod H, Tan B, Malyapa R, et al.: Genotype-guided neoadjuvant therapy for rectal cancer. ASCO Annual Meeting Proceedings; 2005. Abstract 3024.
35. Locker GY, Hamilton S, Harris J, et al.: ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer. J Clin Oncol 2006, 24: 5313-5327.
36. Culy CR, Clemett D, Wiseman LR: Oxaliplatin. A review of its pharmacological properties and clinical eff cacy in metastatic colorectal cancer and its potential in other malignancies. Drugs 2000, 60: 895-924.
37. Reardon JT, Sancar A: Repair of DNA-polypeptide cross links by human excision nuclease. Proc Natl Acad Sci USA 2006, 103: 4056-4061.
38. Shirota Y, Stoehlmacher J, Brabender J, et al.: ERCC1 and thymidylate synthase mRNA levels predict survival for colorectal cancer patients receiving combination oxali-platin and fluorouracil chemotherapy. J Clin Oncol 2001, 19: 4298-4304.
39. Stoehlmacher J, Park DJ, Zhang W, et al.: A multivariate analysis of genomic polymorphisms: prediction of clinical outcome to 5-FU/oxaliplatin combination chemotherapy in refractory colorectal cancer. Br J Cancer 2004, 91: 344-354.
40. Viguier J, Boige V, Miquel C, et al.: ERCC1 codon 118 polymorphism is a predictive factor for the tumor response to oxaliplatin/5-f uorouracil combination chemotherapy in patients with advanced colorectal cancer. Clin Cancer Res 2005, 11: 6212-6217.
41. Cobo M, Isla D, Massuti B, et al.: Customizing cisplatin based on quantitative excision repair cross-complementing 1 mRNA expression: a phase III trial in non-small-cell lung cancer. J Clin Oncol 2007, 25: 2747-2754.
42. Topcu Z: DNA topoisomerases as targets for anticancer drugs. J Clin Pharm Ther 2001, 26: 405-416.
43. Innocenti F, Undevia SD, Iyer L, et al.: Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan. J Clin Oncol 2004, 22: 1382-1388.
44. Lenz HJ, Van Cutsem E, Khambata-Ford S, et al.: Multicenter phase II and translational study of cetuximab in metastatic colorectal carcinoma refractory to irinotecan, oxaliplatin, and fluoropyrimidines. J Clin Oncol 2006, 24: 4914-4921.
45. Khambata-Ford S, Garrett CR, Meropol NJ, et al.: Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab. J Clin Oncol 2007, 25: 3230-3237.
46. Di Fiore F, Blanchard F, Charbonnier F, et al.: Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by Cetuximab plus chemotherapy. Br J Cancer 2007, 96: 1166-1169.
47. De Roock W, Piessevaux H, De Schutter J, et al.: KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab. Ann Oncol 2008, 19: 508-515.
48. Lievre A, Bachet JB, Boige V, et al.: KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. J Clin Oncol 2008, 26: 374-379.
49. Van Cutsem E, Lang I, D'haens G, et al.: KRAS status and eff cacy in the first-line treatment of patients with meta-static colorectal cancer (mCRC) treated with FOLFIRI with or without cetuximab: the CRYSTAL experience [abstract 2]. J Clin Oncol 2008, 26(Suppl): 5.
50. Bokemeyer C, Bondarenko I, Hartmann JT, et al.: KRAS status and eff cacy of first-line treatment of patients with metastatic colorectal cancer (mCRC) with FOLFOX with or without cetuximab: the OPUS experience [abstract 4000]. J Clin Oncol 2008, 26(Suppl): 178.
51. Tejpar S, Peeters M, Humblet Y, et al.: Relationship between the eff cacy with KRAS status (wild-type versus mutant) in patients with irinotecan-refractory metastatic colorectal cancer (mCRC) [abstract 4001]. J Clin Oncol 2008, 26(Suppl): 178.
52. Punt C, Tol J, Rodenburg CJ, et al.: Randomized phrase III study of capecitabine, oxaliplatin, and bevacizumab with or without cetuximab in advanced colorectal cancer (ACC), the CAIRO2 study of the Dutch Colorectal Cancer Group (DCCG). J Clin Oncol 2008, 26(Suppl): 4011.